Quince Therapeutics, Inc. (QNCX) Stock Forecast & Price Target
Quince Therapeutics, Inc. · NASDAQ
$32.33-1.15 (-3.43%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Quince Therapeutics, Inc, 3 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $4.00 to $82.00 (about 20.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $40.25 sits 24% above the current $32.33. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.86 next quarter toward $-4.68 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Quince Therapeutics, Inc.
As of Aug, 3 of 5 firms rate QNCX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
QNCX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.86
Range $-1.02 – $-0.71 · 2 analysts · -99% YoY
Next period, 2 analysts expect Quince Therapeutics, Inc. to earn $-0.86 a share (range $-1.02 – $-0.71), versus $-152.00 a year earlier. Full-year consensus is $-3.65, growing to $-4.68 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Quince Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on QNCX.
#1
Jonathan Wolleben
JMP Securities · Rank #31
Hold
No targeton QNCX
Overall win rate
47%
+ Follow
#2
Leland Gershell
Oppenheimer · Rank #302
Buy
$2000.00+6086.2% to target
Overall win rate
37%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton QNCX
Overall win rate
22%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #417
Hold
No targeton QNCX
Overall win rate
33%
+ Follow
#5
OB
Olivia Brayer Saunders
Cantor Fitzgerald
Buy
$70.00+116.5% to target
Coverage
—
+ Follow
QNCX stock forecast FAQ
What is QNCX's average 12-month price target?+
The 3 analysts with a live target average $40.25 for Quince Therapeutics, Inc. over the next 12 months, ranging from a $82.00 high to a $4.00 low.
Is QNCX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for QNCX?+
The Street-high target is $82.00 (Oppenheimer), and the Street-low is $4.00 (Leerink Partners). The average of all 3 active targets is $40.25.
How many Wall Street analysts cover QNCX?+
5 analysts have an active rating on Quince Therapeutics, Inc., and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering QNCX?+
Among analysts who currently cover QNCX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #31). Their current call is Hold.
What is Quince Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.86 per share (range $-1.02 – $-0.71) across 2 analysts. Full-year EPS is projected at $-3.65, rising to $-4.68 the following year.
How much revenue is Quince Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading QNCX lately?+
As of Aug, 3 of 5 firms rate QNCX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their QNCX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Oppenheimer
